{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:22:08Z","timestamp":1794864128397,"version":"4.9.1"},"reference-count":39,"publisher":"Bentham Science Publishers Ltd.","issue":"8","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["PPL"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Dysregulation of mevalonate metabolism is a hallmark of tumorigenesis\nand therapy resistance across malignancies, though its role in bladder cancer remains unclear. This\nstudy aimed to elucidate its impact on prognosis and cisplatin chemosensitivity in bladder cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Transcriptomic data and clinical information of bladder cancer patients were obtained\nfrom The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases.\nNon-negative matrix factorization (NMF) was used to cluster mevalonate metabolism-related\ngenes into distinct metabolic subtypes (C1 and C2). Associations between mevalonate\nmetabolism, clinical characteristics, immune infiltration, and cisplatin resistance were analyzed using\nGene Set Variation Analysis (GSVA), Kaplan-Meier survival analysis, single-sample Gene\nSet Enrichment Analysis (ssGSEA), and in vitro experiments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>NMF clustering classified bladder cancer patients into two metabolic subtypes (C1\/C2).\nThe C1, characterized by higher mevalonate metabolism (MVAscore), was associated with a poorer\nprognosis, shorter overall survival (OS), and higher T-stage and pathological grades. Immune\nanalysis showed lower immune cell infiltration in C1. Immune infiltration analysis revealed significantly\nlower immune infiltration levels in the C1. Further analysis revealed a positive correlation\nbetween mevalonate metabolism and platinum resistance, with a notable increase in mevalonate\nmetabolism observed in cisplatin-resistant bladder cancer cells. In vitro, simvastatin inhibited the\nproliferation of bladder cancer cells and enhanced their sensitivity to cisplatin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>Mevalonate metabolism drives BCa heterogeneity and chemoresistance while suppressing\nanti-tumor immunity. Its dysregulation serves as both a prognostic biomarker and a target\nfor therapeutic intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Mevalonate metabolism contributes to cisplatin resistance in bladder cancer and represents\na potential therapeutic target. Simvastatin targeting this pathway enhances the efficacy of\ncisplatin, providing a novel personalized chemotherapy strategy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0109298665403178250806111943","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:03:56Z","timestamp":1757311436000},"page":"597-609","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Mevalonate Metabolic Reprogramming Drives Cisplatin Resistance in Bladder Cancer: Mechanisms and Therapeutic Targeting"],"prefix":"10.2174","volume":"32","author":[{"given":"Qixiang","family":"Fang","sequence":"first","affiliation":[{"name":"Department of Urology, The Second Hospital &amp; Clinical Medical School, Lanzhou University, Lanzhou730000, Gansu,China"},{"name":"Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou730030, Gansu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyu","family":"You","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Hospital &amp; Clinical Medical School, Lanzhou University, Lanzhou730000, Gansu,China"},{"name":"Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou730030, Gansu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Hospital &amp; Clinical Medical School, Lanzhou University, Lanzhou730000, Gansu,China"},{"name":"Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou730030, Gansu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Hospital &amp; Clinical Medical School, Lanzhou University, Lanzhou730000, Gansu,China"},{"name":"Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou730030, Gansu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Hospital &amp; Clinical Medical School, Lanzhou University, Lanzhou730000, Gansu,China"},{"name":"Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou730030, Gansu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingchao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Hospital &amp; Clinical Medical School, Lanzhou University, Lanzhou730000, Gansu,China"},{"name":"Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou730030, Gansu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangliang","family":"Qing","sequence":"additional","affiliation":[{"name":"Department of Urology, Zigong Fourth People's Hospital, Zigong 643000, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4919-8164","authenticated-orcid":true,"given":"Zhilong","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Hospital &amp; Clinical Medical School, Lanzhou University, Lanzhou730000, Gansu,China"},{"name":"Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou730030, Gansu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"Bray F.","year":"2024","unstructured":"Bray F.; Laversanne M.; Sung H.; Ferlay J.; Siegel R.L.; Soerjomataram I.; Jemal A.; Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin  2024,74(3),229-263","journal-title":"CA Cancer J Clin"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.eururo.2015.06.042","volume":"70","author":"Cumberbatch M.G.","year":"2016","unstructured":"Cumberbatch M.G.; Rota M.; Catto J.W.F.; La Vecchia C.; The role of tobacco smoke in bladder and kidney carcinogenesis: A comparison of exposures and meta-analysis of incidence and mortality risks. Eur Urol  2016,70(3),458-466","journal-title":"Eur Urol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.6004\/jnccn.2020.0011","volume":"18","author":"Flaig T.W.","year":"2020","unstructured":"Flaig T.W.; Spiess P.E.; Agarwal N.; Bangs R.; Boorjian S.A.; Buyyounouski M.K.; Chang S.; Downs T.M.; Efstathiou J.A.; Friedlander T.; Greenberg R.E.; Guru K.A.; Guzzo T.; Herr H.W.; Hoffman-Censits J; Hoimes C.; Inman B.A.; Jimbo M; Kader AK; Lele S.M.; Michalski J.; Montgomery J.S.; Nandagopal L; Pagliaro LC; Pal S.K.; Patterson A.; Plimack E.R.; Pohar K.S.; Preston M.A.; Sexton W.J.; Siefker-Radtke A.O.; Tward J.; Wright J.L.; Gurski L.A.; Johnson-Chilla A.; Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw  2020,18(3),329-354","journal-title":"J Natl Compr Canc Netw"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41585-024-00963-y","volume":"22","author":"Leyderman M.","year":"2025","unstructured":"Leyderman M.; Chandrasekar T.; Grivas P.; Li R.; Bhat S; Basnet A.; Shapiro O.; Jacob J.; Daneshvar M.A.; Kord E.; Bratslavsky G.; Goldberg H.; Metastasis development in non-muscle-invasive bladder cancer. Nat Rev Urol  2025,22(6),375-386","journal-title":"Nat Rev Urol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41571-018-0026-y","volume":"15","author":"Vlachostergios P.J.","year":"2018","unstructured":"Vlachostergios P.J.; Faltas B.M.; Treatment resistance in urothelial carcinoma: An evolutionary perspective. Nat Rev Clin Oncol  2018,15(8),495-509","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00018-015-2070-4","volume":"73","author":"Li Z.","year":"2016","unstructured":"Li Z.; Zhang H.; Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression. Cell Mol Life Sci  2016,73(2),377-392","journal-title":"Cell Mol Life Sci"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/j.cmet.2022.09.023","volume":"34","author":"Martin-Perez M.","year":"2022","unstructured":"Martin-Perez M.; Urdiroz-Urricelqui U.; Bigas C.; Benitah S.A.; The role of lipids in cancer progression and metastasis. Cell Metab  2022,34(11),1675-1699","journal-title":"Cell Metab"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"652","DOI":"10.21147\/j.issn.1000-9604.2024.06.05","volume":"36","author":"Li J.","year":"2024","unstructured":"Li J.; Ping P.; Li Y.; Xu X.; Fatty acid metabolism: A new target for nasopharyngeal carcinoma therapy. Chin J Cancer Res  2024,36(6),652-668","journal-title":"Chin J Cancer Res"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4103\/jcar.JCar_15_20","volume":"20","author":"Khan W.","year":"2021","unstructured":"Khan W.; Augustine D.; Rao R.S.; Patil S.; Awan K.H.; Sowmya S.V.; Haragannavar V.C.; Prasad K.; Lipid metabolism in cancer: A systematic review. J Carcinog  2021,20,4","journal-title":"J Carcinog"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.18632\/oncotarget.6304","volume":"7","author":"Wang T.","year":"2016","unstructured":"Wang T.; Seah S.; Loh X.; Chan C.W.; Hartman M.; Goh B.C.; Lee S.C.; Simvastatin-induced breast cancer cell death and deactivation of PI3K\/Akt and MAPK\/ERK signalling are reversed by metabolic products of the mevalonate pathway. Oncotarget  2016,7(3),2532-2544","journal-title":"Oncotarget"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1021\/pr8001645","volume":"7","author":"Wang J.","year":"2008","unstructured":"Wang J.; Yuan Y.; Zhou Y.; Guo L.; Zhang L.; Kuai X.; Deng B.; Pan Z.; Li D.; He F.; Protein interaction data set highlighted with human Ras-MAPK\/PI3K signaling pathways. J Proteome Res  2008,7(9),3879-3889","journal-title":"J Proteome Res"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"9015","DOI":"10.2147\/CMAR.S337873","volume":"13","author":"Huang X.","year":"2021","unstructured":"Huang X.; Wei X.; Qiao S.; Zhang X.; Li R.; Hu S.; Mao H.; Liu P.; Low density lipoprotein receptor (LDLR) and 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) expression are associated with platinum-resistance and prognosis in ovarian carcinoma patients. Cancer Manag Res  2021,13,9015-9024","journal-title":"Cancer Manag Res"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"626971","DOI":"10.3389\/fonc.2021.626971","volume":"11","author":"Guerra B.","year":"2021","unstructured":"Guerra B.; Recio C.; Aranda-Tav\u00edo H.; Guerra-Rodr\u00edguez M.; Garc\u00eda-Castellano J.M.; Fern\u00e1ndez-P\u00e9rez L.; The mevalonate pathway, a metabolic target in cancer therapy. Front Oncol  2021,11,626971","journal-title":"Front Oncol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/ncb2936","volume":"16","author":"Sorrentino G.","year":"2014","unstructured":"Sorrentino G.; Ruggeri N.; Specchia V.; Cordenonsi M.; Mano M.; Dupont S.; Manfrin A.; Ingallina E.; Sommaggio R.; Piazza S.; Rosato A.; Piccolo S.; Del Sal G.; Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol  2014,16(4),357-366","journal-title":"Nat Cell Biol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"15051","DOI":"10.1073\/pnas.0910258107","volume":"107","author":"Clendening J.W.","year":"2010","unstructured":"Clendening J.W.; Pandyra A.; Boutros P.C.; Ghamrasni S.E.; Khosravi F.; Trentin G.A.; Martirosyan A.; Hakem A.; Hakem R.; Jurisica I.; Penn L.Z.; Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci USA  2010,107(34),15051-15056","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.canlet.2016.03.004","volume":"375","author":"G\u00f6bel A.","year":"2016","unstructured":"G\u00f6bel A.; Thiele S.; Browne A.J.; Rauner M.; Zinna V.M.; Hofbauer L.C.; Rachner T.D.; Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells. Cancer Lett  2016,375(1),162-171","journal-title":"Cancer Lett"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41397-024-00346-x","volume":"24","author":"Wei H.","year":"2024","unstructured":"Wei H.; Li Z.; Qian K.; Du W.; Ju L.; Shan D.; Yu M.; Fang Y.; Zhang Y.; Xiao Y.; Wang G.; Wang X.; Unveiling the association between HMG-CoA reductase inhibitors and bladder cancer: A comprehensive analysis using Mendelian randomization, animal models, and transcriptomics. Pharmacogenomics J  2024,24(5),24","journal-title":"Pharmacogenomics J"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.cmet.2019.04.002","volume":"30","author":"Ma X.","year":"2019","unstructured":"Ma X.; Bi E.; Lu Y.; Su P.; Huang C.; Liu L.; Wang Q.; Yang M.; Kalady M.F.; Qian J.; Zhang A.; Gupte A.A.; Hamilton D.J.; Zheng C.; Yi Q.; Cholesterol induces CD8 T cell exhaustion in the tumor microenvironment. Cell Metab  2019,30(1),143-156.e5","journal-title":"Cell Metab"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"pp.57-58","DOI":"10.1124\/jpet.057.129185","volume":"389","author":"Zhang R.","year":"2024","unstructured":"Zhang R.; Hohl R.; Neighbors J.D.; Koubek E.J.; Joel R.M.; Reed J.L.; The role of the mevalonate pathway in post-translational modifications of PD-L1. J Pharmacol Experim Ther  2024,389,pp.57-58","journal-title":"J Pharmacol Experim Ther"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1186\/s12885-022-09385-8","volume":"22","author":"Takada K.","year":"2022","unstructured":"Takada K.; Shimokawa M.; Takamori S.; Shimamatsu S.; Hirai F.; Tagawa T.; Okamoto T.; Hamatake M.; Tsuchiya-Kawano Y.; Otsubo K.; Inoue K.; Yoneshima Y.; Tanaka K.; Okamoto I.; Nakanishi Y.; Mori M.; A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: A multicenter retrospective study. BMC Cancer  2022,22(1),503","journal-title":"BMC Cancer"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3322\/caac.21631","volume":"70","author":"Patel V.G.","year":"2020","unstructured":"Patel V.G.; Oh W.K.; Galsky M.D.; Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin  2020,70(5),404-423","journal-title":"CA Cancer J Clin"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1186\/s12964-024-01857-7","volume":"22","author":"Wilczy\u0144ski B.","year":"2024","unstructured":"Wilczy\u0144ski B.; D\u0105browska A.; Kulbacka J.; Baczy\u0144ska D.; Chemoresistance and the tumor microenvironment: The critical role of cell\u2013cell communication. Cell Commun Signal  2024,22(1),486","journal-title":"Cell Commun Signal"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"100938","DOI":"10.1016\/j.drup.2023.100938","volume":"68","author":"Li F.","year":"2023","unstructured":"Li F.; Zheng Z.; Chen W.; Li D.; Zhang H.; Zhu Y.; Mo Q.; Zhao X.; Fan Q.; Deng F.; Han C.; Tan W.; Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms. Drug Resist Updat  2023,68,100938","journal-title":"Drug Resist Updat"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1007\/s13277-014-2959-9","volume":"36","author":"Greife A.","year":"2015","unstructured":"Greife A.; Tukova J.; Steinhoff C.; Scott S.D.; Schulz W.A.; Hatina J.; Establishment and characterization of a bladder cancer cell line with enhanced doxorubicin resistance by mevalonate pathway activation. Tumour Biol  2015,36(5),3293-3300","journal-title":"Tumour Biol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s00280-014-2412-1","volume":"73","author":"Stoehr M.","year":"2014","unstructured":"Stoehr M.; Mozet C.; Boehm A.; Aigner A.; Dietz A.; Wichmann G.; Simvastatin suppresses head and neck squamous cell carcinoma ex vivo and enhances the cytostatic effects of chemotherapeutics. Cancer Chemother Pharmacol  2014,73(4),827-837","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1016\/j.ejca.2014.08.005","volume":"50","author":"Kim S.T.","year":"2014","unstructured":"Kim S.T.; Kang J.H.; Lee J.; Park S.H.; Park J.O.; Park Y.S.; Lim H.Y.; Hwang I.G.; Lee S.C.; Park K.W.; Lee H.R.; Kang W.K.; Simvastatin plus capecitabine\u2013cisplatin versus placebo plus capecitabine\u2013cisplatin in patients with previously untreated advanced gastric cancer: A double-blind randomised phase 3 study. Eur J Cancer  2014,50(16),2822-2830","journal-title":"Eur J Cancer"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1002\/cncr.25790","volume":"117","author":"Han J.Y.","year":"2011","unstructured":"Han J.Y.; Lim KY; Yu S.Y.; Yun T.; Kim H.T.; Lee J.S.; A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive-disease small cell lung cancer. Cancer  2011,117(10),2178-2185","journal-title":"Cancer"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"649551","DOI":"10.3389\/fimmu.2021.649551","volume":"12","author":"Ye H.","year":"2021","unstructured":"Ye H.; Li T.; Wang H.; Wu J.; Yi C.; Shi J.; Wang P.; Song C.; Dai L.; Jiang G.; Huang Y.; Yu Y.; Li J.; TSPAN1, TMPRSS4, SDR16C5, and CTSE as novel panel for pancreatic cancer: A bioinformatics analysis and experiments validation. Front Immunol  2021,12,649551","journal-title":"Front Immunol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-05-0259","volume":"11","author":"Wild P.J.","year":"2005","unstructured":"Wild P.J.; Herr A.; Wissmann C.; Stoehr R.; Rosenthal A.; Zaak D.; Simon R.; Knuechel R.; Pilarsky C.; Hartmann A.; Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin Cancer Res  2005,11(12),4415-4429","journal-title":"Clin Cancer Res"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1006\/scdb.2000.0162","volume":"11","author":"Medd P.G.","year":"2000","unstructured":"Medd P.G.; Chain B.M.; Protein degradation in MHC class II antigen presentation: Opportunities for immunomodulation. Semin Cell Dev Biol  2000,11(3),203-210","journal-title":"Semin Cell Dev Biol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s13046-019-1301-1","volume":"38","author":"Luo X.","year":"2019","unstructured":"Luo X.; Li N.; Zhao X.; Liao C.; Ye R.; Cheng C.; Xu Z.; Quan J.; Liu J.; Cao Y.; DHRS2 mediates cell growth inhibition induced by Trichothecin in nasopharyngeal carcinoma. J Exp Clin Cancer Res  2019,38(1),300","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"13203","DOI":"10.3390\/ijms232113203","volume":"23","author":"Larrea E.","year":"2022","unstructured":"Larrea E.; Fern\u00e1ndez-Rubio C.; Pe\u00f1a-Guerrero J.; Guruceaga E.; Nguewa P.A.; The BRCT domain from the homologue of the oncogene PES1 in Leishmania major (LmjPES) promotes malignancy and drug resistance in mammalian cells. Int J Mol Sci  2022,23(21),13203","journal-title":"Int J Mol Sci"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"5037","DOI":"10.3892\/mmr.2018.8533","volume":"17","author":"Zhang Z.","year":"2018","unstructured":"Zhang Z.; Wang Y.; Zhang J.; Zhong J.; Yang R.; COL1A1 promotes metastasis in colorectal cancer by regulating the WNT\/PCP pathway. Mol Med Rep  2018,17(4),5037-5042","journal-title":"Mol Med Rep"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.5114\/aoms.2018.73129","volume":"18","author":"Li Y.","year":"2019","unstructured":"Li Y.; Cheng X.; Yan J.; Jiang S.; CTHRC1 facilitates bladder cancer cell proliferation and invasion through regulating the PI3K\/Akt signaling pathway. Arch Med Sci  2019,18(1),183-194","journal-title":"Arch Med Sci"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12935-017-0469-8","volume":"17","author":"Chen G.","year":"2017","unstructured":"Chen G.; Wang D.; Zhao X.; Cao J.; Zhao Y.; Wang F.; Bai J.; Luo D.; Li L.; miR-155-5p modulates malignant behaviors of hepatocellular carcinoma by directly targeting CTHRC1 and indirectly regulating GSK-3\u03b2-involved Wnt\/\u03b2-catenin signaling. Cancer Cell Int  2017,17(1),118","journal-title":"Cancer Cell Int"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1038\/jid.2011.41","volume":"131","author":"Zhao Y.","year":"2011","unstructured":"Zhao Y.; Gartner U.; Smith F.J.D.; McLean W.H.I.; Statins downregulate K6a promoter activity: A possible therapeutic avenue for pachyonychia congenita. J Invest Dermatol  2011,131(5),1045-1052","journal-title":"J Invest Dermatol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/gcc.20928","volume":"51","author":"Ono H.","year":"2012","unstructured":"Ono H.; Hiraoka N.; Lee Y.S.; Woo S.M.; Lee W.J.; Choi I.J.; Saito A.; Yanagihara K.; Kanai Y; Ohnami S.; Chiwaki F.; Sasaki H.; Sakamoto H.; Yoshida T.; Saeki N.; Prostate stem cell antigen, a presumable organ-dependent tumor suppressor gene, is down-regulated in gallbladder carcinogenesis. Genes Chromosomes Cancer  2012,51(1),30-41","journal-title":"Genes Chromosomes Cancer"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1006\/bbrc.2000.3393","volume":"275","author":"Bahrenberg G.","year":"2000","unstructured":"Bahrenberg G.; Brauers A.; Joost H.G.; Jakse G.; Reduced expression of PSCA, a member of the LY-6 family of cell surface antigens, in bladder, esophagus, and stomach tumors. Biochem Biophys Res Commun  2000,275(3),783-788","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s00345-013-1037-z","volume":"31","author":"Gakis G.","year":"2013","unstructured":"Gakis G.; Stenzl A.; Gender-specific differences in muscle-invasive bladder cancer: The concept of sex steroid sensitivity. World J Urol  2013,31(5),1059-1064","journal-title":"World J Urol"}],"container-title":["Protein &amp; Peptide Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298665403178250806111943","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/244976\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298665403178250806111943","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T11:36:56Z","timestamp":1764070616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/244976\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0109298665403178250806111943","relation":{},"ISSN":["0929-8665"],"issn-type":[{"value":"0929-8665","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-03-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}